Charles River Laboratories (CRL): financials, SEC filings and peers
Charles River Laboratories (CRL) is a life sciences tools & services company in the Health Care sector of the S&P 500, headquartered in Wilmington, Massachusetts.
It was founded in 1947 and joined the S&P 500 on May 14, 2021.
Its fiscal year ends in December, and its shares trade on the NYSE.
In its SEC filings it is classified as “Services-Commercial Physical & Biological Research”.
Charles River Laboratories at a glance
- Revenue (12 months)
- $4.0B
- Revenue growth
- -0.7%
- Operating margin
- 2.3%
- Net income (12 months)
- −$238M
- Free cash flow (12 months)
- $371M
- Cash
- $192M
- Debt
- $2.6B
- Diluted EPS (12 months)
- $-4.79
Twelve months to June 27, 2026, from the 10-Q filed August 5, 2026.
Latest twelve months
Over the twelve months to June 27, 2026, Charles River Laboratories reported revenue of $4.0 billion, about the same as a year earlier (-0.7%).
Its operating margin was 2.3%: for every $100 of sales, about $2 was left as operating profit.
Charles River Laboratories reported a net loss of $238 million over the period.
Operating cash flow was $582 million and capital spending $212 million, leaving free cash flow of $371 million (9.3% of revenue).
At the end of the period it held $192 million in cash and $2.6 billion in debt, a net debt position of $2.4 billion.
The diluted share count fell 2.6% in a year, typically the result of buybacks.
Five-year trend
- Revenue went from $2.9 billion in fiscal 2020 to $4.0 billion in fiscal 2025, about 6.5% a year.
- Operating margin narrowed from 14.8% to 0.6% over the same years.
- Free cash flow was positive in each of the last 6 fiscal years.
- Charles River Laboratories reported a net loss in 1 of the last 6 fiscal years.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $3.5B | $4.0B | $4.1B | $4.0B | $4.0B |
| Revenue growth | 21.1% | 12.3% | 3.9% | -1.9% | -0.9% |
| Operating margin | 16.7% | 16.4% | 14.9% | 5.6% | 0.6% |
| Net income | $391M | $486M | $475M | $22M | −$144M |
| Free cash flow | $532M | $295M | $365M | $502M | $518M |
| Diluted EPS | $7.60 | $9.48 | $9.22 | $0.20 | $-2.91 |
Fiscal years as reported in Charles River Laboratories’s 10-K filings. Free cash flow is operating cash flow minus capital spending.
Recent SEC filings
- 8-K filed September 24, 2026 — Regulation FD disclosure
- 10-Q filed August 5, 2026 — quarterly report
- 8-K filed August 5, 2026 — Earnings results
- 8-K filed May 11, 2026 — Executive or director change; Shareholder vote results
- 10-Q filed May 7, 2026 — quarterly report
- 8-K filed May 7, 2026 — Earnings results
- 8-K filed February 25, 2026 — Regulation FD disclosure
- 8-K filed February 18, 2026 — Executive or director change
Companies like Charles River Laboratories
Other S&P 500 companies in Life Sciences Tools & Services:
- AAgilent TechnologiesSanta Clara, California
- DHRDanaher CorporationWashington, D.C.
- ILMNIllumina, Inc.San Diego, California
- IQVIQVIADurham, North Carolina
- MTDMettler ToledoColumbus, Ohio
- TECHBio-TechneMinneapolis, Minnesota
- TMOThermo Fisher ScientificWaltham, Massachusetts
- WATWaters CorporationMilford, Massachusetts
More from Health Care
Questions about Charles River Laboratories
Is Charles River Laboratories's revenue growing?
No. Revenue for the twelve months to June 27, 2026 was $4.0 billion, down 0.7% from a year earlier, according to its SEC filings.
Is Charles River Laboratories profitable?
Not over the latest twelve months: it reported a net loss of $238 million for the period to June 27, 2026.
Does Charles River Laboratories have more cash or more debt?
At June 27, 2026 it had $192 million in cash and $2.6 billion in debt, so more debt than cash.
When did Charles River Laboratories last file financial results?
Its latest quarterly report (10-Q) was filed with the SEC on August 5, 2026.
Which companies are similar to Charles River Laboratories?
In the S&P 500, Charles River Laboratories is grouped in Life Sciences Tools & Services within the Health Care sector. Agilent Technologies (A), Danaher Corporation (DHR), Illumina, Inc. (ILMN), IQVIA (IQV), Mettler Toledo (MTD) are in the same group.
Understand the numbers
Source: Charles River Laboratories’s filings with the U.S. Securities and Exchange Commission (EDGAR), retrieved September 27, 2026. Figures are as reported by the company and may be restated. This page is for information only and is not financial advice.